Ann: FY24 Revenue Guidance Upgrade to $12.5M, page-44

K Man

Totally agree - I have actually started to think about BIO's prospects in even more simple terms as follows

• I suspect BIO will exceed their revised forecast of $12.5 million for 23/24 and reckon it could well be closer to $13.5 - $14 million

A very much back of the envelope approach to my thinking is as follows

• Assume $13.5 million for 23/24 - that would be an amazing and circa 90% growth on last years (from memory) $7.2 million in sales.

• Take a conservative view and as such assume a diminishing annual sales growth rate and drop 90% back to say 70% for 24/25 - $13.5 sales grows to $23 million

• Drop growth rate again for 25/26 to say 55% - $23 sales grows to $36 million

• Drop growth again for 26/27 to say 40% - $36 sales becomes $51 million

• Drop growth again for 27/28 to say 30% - $51 sales becomes $67 million

So even with a falling annual growth BIO is selling/growing like crazy

The exciting prospect therefore is where this company might be in terms of $$ sales if they maintain high growth levels - simply put if growth diminishes at a slower pace than the examples above.

A hugely exciting few years ahead if BIO keeps executing strategy as they have to date, keep developing great products and keep expanding sales networks both here and overseas - for example the UK market has 76 million people and is 3 times the size of the Australian market - what do things look like if that really grabs and or they start accelerating into European and Asian markets and so on.

It is the compounding potential of annualised % growth to sales volume that is so exciting for mine.

People can play with the annualised % growth numbers above and you will see what I mean

Very happy to be long in this one and holding onto every share I have

DYOR and good luck to all holders